Remix Therapeutics
Hiring · 7 open jobsGeneral information
Remix Therapeutics develops small molecule therapeutics that modulate RNA processing. Its REMaster Platform is a proprietary drug discovery platform for designing small molecules that control RNA processing. REM-422, its lead program, is an investigational first-in-class small molecule mRNA degrader that targets the pre-mRNA of MYB. The company is headquartered in Watertown, Massachusetts.
Remix Therapeutics is private. In June 2026 it announced a merger with Passage Bio, alongside a $100 million private placement.1
Hiring activity
New jobs added per week2
View these weekly figures as a table
| Week beginning | New listings |
|---|---|
| September 7, 2026 | 1 |
| September 14, 2026 | 1 |
| September 21, 2026 | 1 |
| September 28, 2026 | 1 |
| October 5, 2026 | 0 |
| October 12, 2026 | 1 |
| October 19, 2026 | 0 |
| October 26, 2026 (in progress) | 2 |
Open jobs
7 open · updated todayPage 1 of 1, most recently added first · Download (CSV)3
Want to know which of these 7 jobs are worth your time? Upload your CV and we'll score how well you match each one before you apply. It's free.
Score your CV for free before you applySimilar companies
Common questions
Is Remix Therapeutics hiring now?
Yes. There are 7 open jobs, with 4 added in the last 30 days.
Interview OS
Company pages built from direct checks of real hiring systems.
Notes & sources
- 1. Company description. Written by InterviewOS from Remix Therapeutics's public materials and press coverage; facts are checked against the sources below.
- 2. Weekly counts. A count is the number of listings the pipeline saw for the first time in that week. Weeks begin Monday; the onboarding week is excluded from the scale and every average.
- 3. Live counts. Deduplicated live listings observed daily on Remix Therapeutics's own hiring system; last check October 28, 2026. Stale and syndicated posts on aggregator sites are not counted.
Sources
remixtherapeutics.com
About the data
Report a data issue with this page




